Table 2.

VLS performance of individual DOLPHIN models evaluated as the area under their ROC curves. Three to fourteen active type-II compounds per kinase were recognized in a set of 391 kinase ligands.

ABL1	AUC	BRAF1	AUC
2qohA	0.95	2fb8B	0.98
2qohB	0.95	2fb8A	0.97
2g2iA	0.95
2g2iB	0.94
2f4jA	0.93	LCK	AUC
2hz4B	0.91	2ofuA	0.97
2gqgB	0.91	3lckA	0.97
2hz4A	0.89	1qpcA	0.96
2z60Ab	0.88	1qpeA	0.96
2gqgAa	0.83	2of2A	0.95
2v7aAb	0.81	2of4A	0.95
2hz4C	0.73	1qpjA	0.92
2v7aBb	0.66	1qpdA	0.92

KIT	AUC	SRC	AUC
1pkgBa	0.96	2oiqBa	0.96
1pkgAa	0.92	2bdjAa	0.96
		1yi6Ba	0.94
MK14	AUC	1y57A	0.93
1oz1A	0.97	2bdfBa	0.91
1oukA	0.97	2bdfAa	0.90
1ouyA	0.95	1yi6A	0.82
1m7qA	0.95	1fmkAc	0.77
2okrD	0.94	2hwoAd	0.73
2okrA	0.93	1yomBd	0.50

^aNarrow pocket

^bT315I imatinib-resistant mutation

^cConserved salt bridge disrupted

^dConserved salt bridge disordered.